Invitrogen Shows That Not All Life Science is Created Equal
Invitrogen's performance in 2003 indicates some of the variables involved in determining who can weather the pinch in life sciences spending. The company's experiences indicate that some sectors of life sciences--and thus pharma and biotech R&D--are doing well even if others are not. Invitrogen's cell culture business in particular is growing 30% a year due to changes in the nature of the market, and its new fluorescent probe business, acquired earlier this year, is also doing well.
You may also be interested in...
The Dutch start-up will use the funds to finalize product design for a neurostimulation platform targeting chronic migraines.
Signifier Medical Technologies is ramping up commercialization of its technology solutions for patients with snoring and sleep disordered breathing conditions.
Jeff Shuren, director of the US FDA’s device center, says the agency is working on a draft guidance document that will give industry recommendations on how it should handle products granted emergency use authorization during the COVID-19 public health emergency. The guidance will also address already-approved devices that were modified by their makers under enforcement discretion.